Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Digital PCR-based T Cell Quantification Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange M, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GP, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Aug 9. pii: molcanres.0114.2018. doi: 10.1158/1541-7786.MCR-18-0114. [Epub ahead of print]

PMID:
30093564
2.

RNA-seq analysis of Lgr6+ stem cells and identification of an Lgr6 isoform.

van de Glind GC, Bastidas Torres AN, Zoutman WH, van der Zeeuw SAJ, Kiełbasa SM, de Gruijl FR, Tensen CP.

Exp Dermatol. 2017 Oct 7. doi: 10.1111/exd.13453. [Epub ahead of print]

PMID:
28987003
3.

Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.

Iżykowska K, Przybylski GK, Gand C, Braun FC, Grabarczyk P, Kuss AW, Olek-Hrab K, Bastidas Torres AN, Vermeer MH, Zoutman WH, Tensen CP, Schmidt CA.

Oncotarget. 2017 Jun 13;8(24):39627-39639. doi: 10.18632/oncotarget.17383.

4.

Accurate Quantification of T Cells by Measuring Loss of Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR Assays.

Zoutman WH, Nell RJ, Versluis M, van Steenderen D, Lalai RN, Out-Luiting JJ, de Lange MJ, Vermeer MH, Langerak AW, van der Velden PA.

J Mol Diagn. 2017 Mar;19(2):236-243. doi: 10.1016/j.jmoldx.2016.10.006. Epub 2016 Dec 22.

PMID:
28012713
5.

Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome.

Boonk SE, Zoutman WH, Putter H, Ram-Wolff C, Felcht M, Klemke CD, Ranki A, Quaglino P, Whittaker S, Bagot M, Willemze R, Vermeer MH.

J Invest Dermatol. 2017 Mar;137(3):754-757. doi: 10.1016/j.jid.2016.10.025. Epub 2016 Oct 28. No abstract available.

6.

Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.

van Doorn R, Slieker RC, Boonk SE, Zoutman WH, Goeman JJ, Bagot M, Michel L, Tensen CP, Willemze R, Heijmans BT, Vermeer MH.

J Invest Dermatol. 2016 Sep;136(9):1876-84. doi: 10.1016/j.jid.2016.03.042. Epub 2016 Apr 23. Review.

7.

Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients.

Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ, Tosi I, Morris SL, Moriarty B, Booken N, Felcht M, Quaglino P, Ponti R, Barberio E, Ram-Wolff C, Jäntti K, Ranki A, Bernengo MG, Klemke CD, Bensussan A, Michel L, Whittaker S, Bagot M, Tensen CP, Willemze R, Vermeer MH.

J Invest Dermatol. 2016 Jul;136(7):1364-1372. doi: 10.1016/j.jid.2016.01.038. Epub 2016 Feb 28.

8.

EPHA4 is overexpressed but not functionally active in Sézary syndrome.

Hameetman L, van der Fits L, Zoutman WH, Out-Luiting JJ, Siegal G, de Esch IJ, Vermeer MH, Tensen CP.

Oncotarget. 2015 Oct 13;6(31):31868-76. doi: 10.18632/oncotarget.5573.

9.

Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma.

Gao L, van den Hurk K, Nsengimana J, Laye JP, van den Oord JJ, Beck S, Gruis NA, Zoutman WH, van Engeland M, Newton-Bishop JA, Winnepenninckx VJ, van Doorn R.

J Invest Dermatol. 2015 Sep;135(9):2328-2331. doi: 10.1038/jid.2015.163. Epub 2015 Apr 28. No abstract available.

10.

Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment.

Halkes CJM, Zoutman WH, van der Fits L, Jedema I, Vermeer MH.

J Invest Dermatol. 2015 Apr;135(4):1199-1202. doi: 10.1038/jid.2014.501. Epub 2014 Nov 28. No abstract available.

11.

Diagnostic and prognostic significance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fungoides and primary cutaneous CD30-positive lymphoproliferative disease.

Nicolae-Cristea AR, Benner MF, Zoutman WH, van Eijk R, Jansen PM, Tensen CP, Willemze R.

Br J Dermatol. 2015 Mar;172(3):784-8. doi: 10.1111/bjd.13476. Epub 2015 Jan 26. No abstract available.

PMID:
25308604
12.

Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

van der Fits L, Out-Luiting JJ, Tensen CP, Zoutman WH, Vermeer MH.

J Invest Dermatol. 2014 Oct;134(10):2639-2647. doi: 10.1038/jid.2014.199. Epub 2014 Apr 22.

13.

Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.

Koens L, Zoutman WH, Ngarmlertsirichai P, Przybylski GK, Grabarczyk P, Vermeer MH, Willemze R, Jansen PM, Schmidt CA, Tensen CP.

J Invest Dermatol. 2014 Jan;134(1):290-292. doi: 10.1038/jid.2013.265. Epub 2013 Jun 13. No abstract available.

14.

A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides.

van Kester MS, Borg MK, Zoutman WH, Out-Luiting JJ, Jansen PM, Dreef EJ, Vermeer MH, van Doorn R, Willemze R, Tensen CP.

J Invest Dermatol. 2012 Aug;132(8):2050-9. doi: 10.1038/jid.2012.117. Epub 2012 Apr 19.

15.

Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.

van Linden OP, Farenc C, Zoutman WH, Hameetman L, Wijtmans M, Leurs R, Tensen CP, Siegal G, de Esch IJ.

Eur J Med Chem. 2012 Jan;47(1):493-500. doi: 10.1016/j.ejmech.2011.11.020. Epub 2011 Nov 18.

PMID:
22137457
16.

A restricted clonal T-cell receptor αβ repertoire in Sézary syndrome is indicative of superantigenic stimulation.

van der Fits L, Sandberg Y, Darzentas N, Zoutman WH, Tielemans D, Wolvers-Tettero IL, Vermeer MH, Langerak AW.

Br J Dermatol. 2011 Jul;165(1):78-84. doi: 10.1111/j.1365-2133.2011.10308.x. Epub 2011 Jun 2.

PMID:
21410672
17.

MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.

van der Fits L, van Kester MS, Qin Y, Out-Luiting JJ, Smit F, Zoutman WH, Willemze R, Tensen CP, Vermeer MH.

J Invest Dermatol. 2011 Mar;131(3):762-8. doi: 10.1038/jid.2010.349. Epub 2010 Nov 18.

18.

Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type.

Senff NJ, Zoutman WH, Vermeer MH, Assaf C, Berti E, Cerroni L, Espinet B, de Misa Cabrera RF, Geerts ML, Kempf W, Mitchell TJ, Paulli M, Petrella T, Pimpinelli N, Santucci M, Whittaker SJ, Willemze R, Tensen CP.

J Invest Dermatol. 2009 May;129(5):1149-55. doi: 10.1038/jid.2008.357. Epub 2008 Nov 20.

19.

Absence of germline epimutation of the CDKN2A gene in familial melanoma.

van Doorn R, Zoutman WH, Gruis NA.

J Invest Dermatol. 2009 Mar;129(3):781-4. doi: 10.1038/jid.2008.287. Epub 2008 Sep 25. No abstract available.

20.

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.

van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS, Huang TH, Tensen CP.

J Clin Oncol. 2005 Jun 10;23(17):3886-96. Epub 2005 May 16.

PMID:
15897551
21.

A lack of Birbeck granules in Langerhans cells is associated with a naturally occurring point mutation in the human Langerin gene.

Verdijk P, Dijkman R, Plasmeijer EI, Mulder AA, Zoutman WH, Mieke Mommaas A, Tensen CP.

J Invest Dermatol. 2005 Apr;124(4):714-7.

Supplemental Content

Loading ...
Support Center